Alteogen (196170 KS): Distinct Platform Technology; Biosimilar Pipeline; Potential Value Unlocking
Alteogen’s formulation platform change technology is in constant demand. The company can be potential first-mover in Eylea biosimilar. Its...
573 Views
Santen Pharmaceutical (4536 JP): Future Is Uncertain Beyond Eylea
Santen’s key drug to face biosimilar competition is the major overhang on the company’s near-term growth potential. The company does not have any...
425 Views
U.S. Equity Strategy: Several Indicators Suggest a Pullback Likely
Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight...
545 Views
U.S. Equities: Test Of The Lows Coming?
Now that the initial/primary low has been established and with the S&P 500 roughly 20% off the lows, we believe it is time to map out potential...
482 Views
Mylan N.V. (MYL US): Another Contrarian Pharmaceutical Investment
Mylan Nv (MYL US)Â stock has seen some downward pressure since 2015 after the increased capital expenditure and debt load for acquisitions...
558 Views
No more insights